↓ Skip to main content

Dove Medical Press

Article Metrics

Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment

Overview of attention for article published in HIV/AIDS (Auckland, N.Z.), January 2013
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (51st percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 tweeters

Readers on

mendeley
10 Mendeley
Title
Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
Published in
HIV/AIDS (Auckland, N.Z.), January 2013
DOI 10.2147/hiv.s24432
Pubmed ID
Authors

Eric W Pefura Yone, André P Kengne

Abstract

An extended-release formulation of nevirapine (NVP-XR) has been developed with the aim of simplifying antiretroviral treatment regimens and improving patients' adherence with a single daily intake. The VERxVE and TRANxITION clinical trials have demonstrated the noninferiority of NVP-XR compared with nevirapine immediate-release (NVP-IR) on viral load after 24 and 48 months of treatment. The tolerance profiles of NVP-XR and NVP-IR are similar. Simplifying the treatment dosage for NVP would likely improve adherence to antiretroviral treatments.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 10 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
South Africa 1 10%
Unknown 9 90%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 30%
Student > Master 2 20%
Student > Ph. D. Student 1 10%
Student > Bachelor 1 10%
Student > Doctoral Student 1 10%
Other 2 20%
Readers by discipline Count As %
Medicine and Dentistry 7 70%
Social Sciences 1 10%
Business, Management and Accounting 1 10%
Unknown 1 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 January 2013.
All research outputs
#2,494,490
of 5,036,908 outputs
Outputs from HIV/AIDS (Auckland, N.Z.)
#45
of 86 outputs
Outputs of similar age
#130,027
of 287,428 outputs
Outputs of similar age from HIV/AIDS (Auckland, N.Z.)
#4
of 8 outputs
Altmetric has tracked 5,036,908 research outputs across all sources so far. This one is in the 47th percentile – i.e., 47% of other outputs scored the same or lower than it.
So far Altmetric has tracked 86 research outputs from this source. They receive a mean Attention Score of 2.2. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 287,428 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.